NHC Stock Analysis: National HealthCare | NYSE MKT
Medical Care Facilities | NYSE MKT, USA | Market Cap: 3.574m USD | 12M Return: 104.1% | US6359061008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.6M
EPS Trend: 80.5%
Rev. Trend: 98.2%
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
National HealthCare Corporation (NHC), founded in 1971 and headquartered in Murfreesboro, Tennessee, operates a diversified portfolio of senior care and healthcare services through two reporting segments: Inpatient and Homecare and Hospice Services. Its inpatient operations include skilled nursing facilities, assisted living facilities, independent living facilities, specialty medical units (including memory care for Alzheimers patients and sub-acute nursing units), and behavioral health services for adult and geriatric patients with psychiatric or addictive disorders. The homecare and hospice segment provides in-home medical care, hospice and palliative care, pharmacy services, and managed care insurance solutions. NHC also earns ancillary revenue by providing management, accounting, and financial services to third parties and leasing its owned properties to outside operators.
The skilled nursing and senior living industry serves a structurally aging population, with the U.S. Census Bureau projecting that adults aged 65 and over will represent a growing share of the population over the coming decades, supporting long-term demand for these services. Operators in this GICS sub-industry are typically reimbursed through a mix of Medicare and Medicaid (for skilled nursing), private pay, and managed care arrangements, which makes the segment sensitive to government reimbursement policy and labor cost trends.
- Skilled nursing occupancy gains lift Inpatient segment revenue
- Medicare and Medicaid reimbursement rate changes pressure operator margins
- Homecare and Hospice Services expansion outpaces facility-based care
| Net Income: 140.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.11 > 1.0 |
| NWC/Revenue: 24.71% < 20% (prev 13.34%; Δ 11.38% < -1%) |
| CFO/TA 0.12 > 3% & CFO 188.8m > Net Income 140.3m |
| Net Debt (-183.7m) to EBITDA (233.6m): -0.79 < 3 |
| Current Ratio: 22.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.9m) vs 12m ago 1.70% < -2% |
| Gross Margin: 39.49% > 18% (prev 38.11%; Δ 1.37% > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 93.34%; Δ 7.27% > 0%) |
| Interest Coverage Ratio: 73.58 > 6 (EBIT TTM 187.9m / Interest Expense TTM 2.55m) |
| A: 0.25 (Total Current Assets 403.6m - Total Current Liabilities 18.3m) / Total Assets 1.54b |
| B: 0.58 (Retained Earnings 888.7m / Total Assets 1.54b) |
| C: 0.12 (EBIT TTM 187.9m / Avg Total Assets 1.55b) |
| D: 2.74 (Book Value of Equity 1.12b / Total Liabilities 408.9m) |
| Altman-Z'' = 7.23 = AAA |
| DSRI: 0.91 (Receivables 137.7m/142.1m, Revenue 1.56b/1.46b) |
| GMI: 0.97 (GM 38.11% / 39.49%) |
| AQI: 1.06 (AQ_t 0.24 / AQ_t-1 0.23) |
| SGI: 1.07 (Revenue 1.56b / 1.46b) |
| TATA: -0.03 (NI 140.3m - CFO 188.8m) / TA 1.54b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at USD 224.73 with a total of 94,126 shares traded. Over the past week, the price has changed by -4.03%, over one month by -0.60%, over three months by +18.66% and over the past year by +104.14%.
Current recommended Stop Loss: 213.70 (which is 4.9% or 1.3 ATR below the current price).
National HealthCare has no consensus analysts rating.
| Analysts Target Price | 6.2 | -97.3% |
P/E Trailing = 25.1322
P/E Forward = 9.8912
P/S = 2.2924
P/B = 3.1201
P/EG = 0.8241
Revenue TTM = 1.56b USD
EBIT TTM = 187.9m USD
EBITDA TTM = 233.6m USD
Long Term Debt = 32.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 82.2m USD (corrected: LT Debt 32.5m + ST Debt 18.3m) + Leases 31.4m
Net Debt = -183.7m USD (calculated: Debt 82.2m - CCE 265.9m)
Enterprise Value = 3.39b USD (3.57b + Debt 82.2m - CCE 265.9m)
Interest Coverage Ratio = 73.58 (Ebit TTM 187.9m / Interest Expense TTM 2.55m)
EV/FCF = 23.14x (Enterprise Value 3.39b / FCF TTM 146.5m)
FCF Yield = 4.32% (FCF TTM 146.5m / Enterprise Value 3.39b)
FCF Margin = 9.40% (FCF TTM 146.5m / Revenue TTM 1.56b)
Net Margin = 9.00% (Net Income TTM 140.3m / Revenue TTM 1.56b)
Gross Margin = 39.49% ((Revenue TTM 1.56b - Cost of Revenue TTM 943.4m) / Revenue TTM)
Gross Margin QoQ = 40.71% (prev 38.43%)
Tobins Q-Ratio = 2.21 (Enterprise Value 3.39b / Total Assets 1.54b)
Interest Expense / Debt = 3.11% (Interest Expense 2.55m / Debt 82.2m)
Taxrate = 22.94% (42.5m / 185.4m)
NOPAT = 144.8m (EBIT 187.9m * (1 - 22.94%))
Current Ratio = 22.06 (Total Current Assets 403.6m / Total Current Liabilities 18.3m)
Debt / Equity = 0.07 (Debt 82.2m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = -0.79 (Net Debt -183.7m / EBITDA 233.6m)
Debt / FCF = -1.25 (Net Debt -183.7m / FCF TTM 146.5m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 140.3m / Total Assets 1.54b)
RoE = 12.94% (Net Income TTM 140.3m / Total Stockholder Equity 1.08b)
RoCE = 16.83% (EBIT 187.9m / Capital Employed (Equity 1.08b + L.T.Debt 32.5m))
RoIC = 9.93% (NOPAT 144.8m / Invested Capital 1.46b)
WACC = 7.33% (E(3.57b)/V(3.66b) * Re(7.44%) + D(82.2m)/V(3.66b) * Rd(3.11%) * (1-Tc(0.23)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.38 | Cagr: 1.02%
[DCF] Terminal Value 77.97% ; FCFF base≈128.1m ; Y1≈146.8m ; Y5≈216.1m
[DCF] Fair Price = 219.4 (EV 3.25b - Net Debt -183.7m = Equity 3.44b / Shares 15.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 30.16% | SUE: N/A | # QB: 0
Revenue Correlation: 98.20 | Revenue CAGR: 15.02% | SUE: N/A | # QB: 0